About us

iBody Inc. is a start-up company launched from Nagoya University, Japan, at Feb 2018.
We have pioneered a unique technology of discovering, generating, and producing monoclonal antibodies from single B cells.

Our mission is to contribute human healthcare by lightning monoclonal antibody development.

Name

iBody Inc.

Office

102 Incubation Facility, Nagoya University,

1 Furo-cho, Chikusa-ku, Nagoya, Aichi 464-0814, JAPAN  

​Capital

60,000,000 yen

Established

Feb. 1st, 2018

​Founders

Teruyo Ojima-Kato Ph.D. 

Hideo Nakano Ph.D. (Professor)

Technical Adviser

Yoshihiro Kakeji Ph.D. (Professor, Kobe University)

Shun'ichi Kuroda Ph.D. (Professor, Osaka University)

​Kouhei Tsumoto Ph.D. (Professor, The University of Tokyo)

Work

Screening and Licensing of rabbit monoclonal antibodies for research and diagnostics uses.

Screening and Licensing of human monoclonal antibodies.

Currently we are accepting collaborative research on discovering rabbit monoclonal antibodies and exploring human monoclonal antibodies.

For more details, contact us through an inquiry form or email.

会社所在地 

〒464-0814

愛知県名古屋市千種区不老町1番

​名古屋大学インキュベーション施設102号

Access

102 Incubation Facility, Nagoya University, 1 Furo-cho, Chikusa-ku, Nagoya, Aichi 464-0814, JAPAN 

お問い合わせ / Contact

info@ibody.co.jp

Copyright ©2019 iBody Inc All Rights Reserved.